ReviewClinical and experimental medicine2018
Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes.
Review in Clinical and experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Pharmacologic DPP-4 inhibition promotes CD8bioRxiv : the preprint server for biology · 2026Article
- Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data.BMC medicine · 2025Observational
- A Comprehensive Review of Novel Advances in Type 1 Diabetes Mellitus.Journal of diabetes · 2025Review
- Association of DPP-4 inhibitors with respiratory and cardiovascular complications in patients with COPD: a nationwide cohort study.ERJ open research · 2025Article
- Τhiazolidine-4-One Derivatives with Variable Modes of Inhibitory Action Against DPP4, a Drug Target with Multiple Activities and Established Role in Diabetes Mellitus Type II.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Slow progression of type 1 diabetes associated with pembrolizumab and lenvatinib combination therapy in a patient with probable slowly progressive type 1 diabetes mellitus and endometrial cancer.Diabetology international · 2025Article
- Six-Year Complete Remission of Type-1 Diabetes Mellitus in an Adult Treated With Sitagliptin.Cureus · 2023Article
- Research on ACEI of Low-Molecular-Weight Peptides fromMolecules (Basel, Switzerland) · 2022Article
- Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases.Molecules (Basel, Switzerland) · 2022Review
- Assessment of serum dipeptidyl peptidase-IV levels in autoimmune thyroid disease.The Journal of international medical research · 2022Article
- A Microtube-Based Wearable Closed-Loop Minisystem for Diabetes Management.Research (Washington, D.C.) · 2022Article
- Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitorsFrontiers in immunology · 2022Article
- Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus.Journal of clinical medicine research · 2021Article
- Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales.Frontiers in pharmacology · 2021Review
- Potential Effects of Coronaviruses on the Liver: An Update.Frontiers in medicine · 2021Review
- The Bone-Forming Properties of Periosteum-Derived Cells Differ Between Harvest Sites.Frontiers in cell and developmental biology · 2020Article
- Drug Delivery System in the Treatment of Diabetes Mellitus.Frontiers in bioengineering and biotechnology · 2020Review
- The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: fromTherapeutic advances in chronic disease · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a novel class of anti-diabetic agents confirmed to improve glycemic control and preserve β-cell function in type 2 diabetes. Three major large-scale studies, EXAMINE, SAVOR-TIMI 53, and TECOS, have confirmed the cardiovascular safety profile of DPP-4 inhibitors. Based on these results, DPP-4 inhibitors have gained widespread use in type 2 diabetes treatment. It is currently unknown, however, whether DPP-4 inhibitors have similar therapeutic efficacy against autoimmune diabetes. Several in vitro and in vivo studies have addressed this issue, but the results remain controversial. In this review, we summarize experimental findings and preliminary clinical trial results, and identify potentially effective immune modulation targets of DPP-4 inhibitors for autoimmune diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.